Chembio Diagnostics

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Acquisition will expand commercial presence and market opportunity in Brazil

Chembio Diagnostics Enters into Definitive Agreement to Acquire Orangelife

Innovative HIV Self-Test Uses the World’s Smallest Blood Sample Innovative HIV Self-Test Uses the World’s Smallest Blood Sample

Chembio Diagnostics Receives WHO Prequalification Approval for HIV Self-Test

Expands Manufacturing of HIV Tests for International Markets Expands Manufacturing of HIV Tests for International Markets

Chembio Diagnostics Receives WHO Prequalification Approval for Malaysia Facility

MEDFORD, N.Y., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the closing of a $20 million term loan with an affiliate of Perceptive Advisors, one of the world’s leading healthcare-focused investment firms.

Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors

MEDFORD, N.Y., Aug.  27, 2019  (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in two upcoming investor conferences.

Chembio Diagnostics to Participate in Upcoming Investor Conferences

Chembio Diagnostics, Inc. (CEMI) CEO John Sperzel on Q2 2019 Results - Earnings Call Transcript

Chembio Diagnostics, Inc. (CEMI) CEO John Sperzel on Q1 2019 Results - Earnings Call Transcript

Chembio Diagnostics misses by $0.04, beats on revenue

News for Chembio Diagnostics Stock (CEMI)